Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Acute Sensorineural Global Market 2016 Prospectus, Examination and Forecast to 2021

Thursday, October 13, 2016 20:56
% of readers think this story is Fact. Add your two cents.

(Before It's News)

The report provides comprehensive information on the therapeutics under development for Acute Sensorineural Hearing Loss, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Sensorineural Hearing Loss and features dormant and discontinued projects.


Get Sample Report @


Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.



- The report provides a snapshot of the global therapeutic landscape of Acute Sensorineural Hearing Loss

- The report reviews pipeline therapeutics for Acute Sensorineural Hearing Loss by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Acute Sensorineural Hearing Loss therapeutics and enlists all their major and minor projects

- The report assesses Acute Sensorineural Hearing Loss therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Acute Sensorineural Hearing Loss


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Acute Sensorineural Hearing Loss

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Acute Sensorineural Hearing Loss pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


Buy 1-User PDF @


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Acute Sensorineural Hearing Loss Overview 6

Therapeutics Development 7

Pipeline Products for Acute Sensorineural Hearing Loss – Overview 7

Acute Sensorineural Hearing Loss – Therapeutics under Development by Companies 8

Acute Sensorineural Hearing Loss – Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Acute Sensorineural Hearing Loss – Products under Development by Companies 12

Acute Sensorineural Hearing Loss – Companies Involved in Therapeutics Development 13

Nordmark Arzneimittel GmbH & Co. KG 13

Orbis Biosciences Inc 14

Otologic Pharmaceutics, Inc. 15

Pragma Therapeutics 16

Xigen SA 17

Acute Sensorineural Hearing Loss – Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Combination Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

(acetylcysteine + disufenton sodium) – Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

ancrod – Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

betamethasone valerate ER – Drug Profile 31



Access Report @


Reach Us:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           


Follow Us:




Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.